Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.

Episode 305: FDA and Oncology Clinical Trials

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles 

Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London